Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3259-3278

  Kanwar, Jagat R ^a   Sriramoju, Bhasker ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Blood brain barrier; Brain delivery; Neurological diseases; Targeted nanoparticles

Indexed keywords

BAPINEUZUMAB; BETA1A INTERFERON; CITICOLINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIMEBON; DONEPEZIL; ENALAPRIL; FINGOLIMOD; GALANTAMINE; INTERFERON; INTERFERON BETA SERINE; LAQUINIMOD; LOSARTAN; MEMANTINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NANOCONJUGATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RAMIPRIL; RILUZOLE; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; UNINDEXED DRUG; VALSARTAN; VINCRISTINE;

ALZHEIMER DISEASE; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXCITOTOXICITY; HUMAN; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NANOPHARMACEUTICS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; REVIEW; SURFACE PROPERTY; T LYMPHOCYTE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; HUMANS; MICE; NANOPARTICLES; NERVOUS SYSTEM DISEASES;

EID: 84870309846     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30919     Document Type: Review

References (171)

1. Riggs JE. Age specific rates of neurological disease. In: Hof PR, Mobbs CV, editors. Functional Neurobiology of Aging. San Diego, CA Press: Academic Press; 2001.
2. Calvo P, Gouritin B, Villarroya H, etal. Quantification and localisation of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during allergic encephalomyelitis in the rat. Eur J Neurosci. 2002;15(8):1317-1326.
3. Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov Today. 2005;10(21):1435-1442.
4. Boado RJ. Antisense drug delivery through the blood-brain barrier. Adv Drug Deliv Rev. 1995;15:73-107.
5. Modi G, Pillay V, Choonara YE, Ndesendo VM, Du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009;88(4):272-285.
6. Khlebtsov NG, Dykman LA. Optical properties and biomedical applications of plasmonic nanoparticles. J Quantit Spectrosc Radiat Trans. 2009;12:1-35.
7. Roney C, Kulkarni AR, Arora V, etal. Targeted nanoparticle delivery through blood-brain barrier for Alzheimer's disease. J Control Release. 2005;108(2-3):193-214.
8. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788(4):842-857.
9. Baratchi S, Kanwar RK, Khoshmanesh K, etal. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr Nanosci. 2008;5:1-11.
10. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59(6):454-477.
11. Tanner CM. Epidemiology of Parkinson's disease. Neurol Clin. 1992;109(2):317-329.
12. Finch CE, Day JR. Molecular biology of aging in the nervous system: a synopsis of the levels of mechanisms. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia, PA: Saunders; 1994.
13. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol. 1989;15(1):27-44.
14. Anderton BH. Ageing of the brain. Mech Ageing Dev. 2002;123(7): 811-817.
15. Kurtland LT. Amyotrophic lateral sclerosis and Parkinson's disease complex on Guam linked to an environmental neurotoxin. Trends Neurosci. 1988;11(2):51-54.
16. Przedborski S, Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res. 2001;1(6):407-418.
17. Relja M. Pathophysiology and classification of neurodegenerative diseases. Available from: http://ifcc.org.instant.cohaesio.net/ifccfiles/docs/150309200415.pdf. Accessed September 3, 2011.
18. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(2):303-321.
19. Kanwar JR, Kanwar RK, Burrow H, Baratchi S. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem. 2009;16(19):2373-2394.
20. Clarke PGH. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol. 1990;181(3):195-213.
21. Cui Z, Lockman PR, Atwood CS, etal. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's disease and other CNS diseases. Eur J Pharm Biopharm. 2005;59(2):263-272.
22. Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond). 2009;4(5):541-555.
23. Scheuner D, Eckman C, Jensen M, etal. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
24. Swartz RH, Black SE, St George-Hyslop P. Apolipoprotein E and Alzheimer's disease: A genetic, molecular and neuroimaging review. Can J Neurol Sci. 1999;26(2):77-88.
25. Walsh DM, Klyubin I, Fadeeva JV, etal. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535-539.
26. Lambert MP, Barlow AK, Chromy BA, etal. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448-6453.
27. Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712.
28. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am. 2005;15(4):727-753.
29. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:513-533.
30. Rondi-Reig L, Libbey M, Eichenbaum H, Tonegawa S. CA1-specific N-methyl-D-aspartate receptor knockout mice are deficient in solving a nonspatial transverse patterning task. Proc Natl Acad Sci U S A. 2001;98(6):3543-3548.
31. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2004;142(1): 37-46.
32. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002;99(19): 12197-12202.
33. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128.
34. Schenk D, Barbour R, Dunn W, etal. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.
35. Fleisher AS, Raman R, Siemers ER, etal. Phase 2safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65(8):1031-1038.
36. Bard F, Cannon C, Barbour R, etal. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8): 916-919.
37. DeMattos RB, Bales KR, Cummins DJ, etal. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(15):8850-8855.
38. Fillit H, Hess G, Hill J, Bonner P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009;73(3):180-185.
39. Oddo S, Billings L, Kessiak JP, Cribbs DH, LaFerla FM. Immunotherapy leads to early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321-332.
40. Bachurin S, Bukatina E, Lermontova N, etal. Antihistamine agent dimebon as a novel neuroprotector and cognition enhancer. Ann N Y Acad Sci. 2001;939:425-435.
41. Nagahara AH, Merrill DA, Coppola G, etal. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15(3):331-337.
42. Cramer PE, Cirrito JR, Wesson DW, etal. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficitsinAD mouse models. Science. 2012;335(6075):1503-1506.
43. Michael JZ, Robert EB. Pathophysiology of Parkinson's disease. Neuropsychopharmacology. In: Coyle JT, Charney D, Davis KL, editors. The Fifth Generation of Progress. An Official Publication of the American College of Neuropsychopharmacology. Philidelphia, PA: Lippincott Williams and Wilkins; 1996.
44. Gibb WR, Scott T, Lees AJ. Neuronal inclusions of Parkinson's disease. Mov Disord. 1991;6(1):2-11.
45. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047.
46. Van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet. 2001;69(3): 629-634.
47. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158-1160.
48. Han H, Weinreb PH, Lansbury PTJ. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995;2(3):163-169.
49. Kholodilov NG, Neystat M, Oo TF, etal. Increased expression of rat synuclein1in the substantia nigra pars compacta identified by differential display in a model of developmental target injury. J Neurochem. 1999;73(6):2586-2599.
50. Mcnaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003;179(1):38-46.
51. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992;32(6):804-812.
52. Coskun P, Wyrembak J, Schriner S, etal. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta. 2012;1820(5): 553-564.
53. Karlsborg M, Korbo L, Regeur L, Glad A. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull. 2010;57(6): A4155.
54. Pagonabarraga J, Kulisevsky J. Rasagiline: effectiveness and protection in Parkinson's disease. Rev Neurol. 2010;51(9):535-541.
55. Freed CR, Greene PE, Breeze RE, etal. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344(10):710-719.
56. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors. 1999;9(2-4):267-272.
57. Hunter C, Jankovic J. Double-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early untreated Parkinson's disease. Neurology. 1999;52:214-221.
58. Kordower JH, Palfi S, Chen EY, etal. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999;46(3): 419-434.
59. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the atherosclerosis risk in communities study. Stroke. 2006;37(10):2493-2498.
60. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Timely Top Med Cardiovasc Dis. 2007;11:E24.
61. Karaszewski B, Wardlaw JM, Marshall I, etal. Brain temperature elevation and anaerobic metabolism in human acute ischaemic stroke. Brain. 2009;32(Pt 4):955-964.
62. Nakanishi N, Tu S, Shin Y, etal. Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci. 2009;29(16):5260-5265.
63. Joza N, Susin SA, Daugas E, etal. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001; 410(6828):549-554.
64. Ekshyyan O, Aw TY. Apoptosis in neurodegenerative disorders. Curr Neurovasc Res. 2004;1(4):355-371.
65. Augusto DE, Alvarez LM, Costa FT. Update in spontaneous cerebral hemorrhage. Med Intensiva. 2008;32:282-295.
66. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7(3):243-253.
67. Weyrich AS, Skalabrin EJ, Kraiss LW. Targeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamole. Am J Ther. 2009;16(2):164-170.
68. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998;138(1):11-24.
69. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avb3integrins. Circulation. 1998;98(11):1085-1091.
70. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke. Emerging pharmacological, mechanical and imaging strategies. Stroke. 2005;36(10):2311-2320.
71. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365-372.
72. Abe K. Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy. Rinsho Shinkeigaku. 2008;48(11):896-898. Japanese.
73. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70(2):133-139.
74. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol. 2000;161(2):733-739.
75. Angel I, Strein S, Schatz G, etal. The lipophilic transition modulator DP-b99 attenuates matrix metalloproteinase activity in a rat MCAO ischaemic model. (Abstract). Soc Neurosci. 2004;100:3.
76. Rosenberg G, Angel I, Kozak A. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. Br J Clin Pharmacol. 2005;60(1):7-16.
77. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007;321(3):892-901.
78. Drugs. com [homepage on the Internet]. ReNeuron gives uptake on stroke clinical trial. [press release]. Available from: http://www.drugs.com/clinical_trials/reneuron-gives-update-stroke-clinical-trial-11261.html. Accessed September 6, 2011.
79. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 1999;13(10):1207-1217.
80. Streit WJ, Kincaid-Colton CA. The brain's immune system. Sci Am. 1995;273(5):54-61.
81. Sroga JM, Jones TB, Kigerl KA, McGaughy VM, Popovich PG. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol. 2003;462(2):223-240.
82. Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol. 1998;152(1):74-87.
83. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707-717.
84. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621.
85. Heppner FL, Greter M, Marino D, etal. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med. 2005; 11(2):146-152.
86. Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med. 18, 2011; 63:389-404.
87. Cepok S, Rosche, Grummel V, etal. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128(Pt 7):1667-1676.
88. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A. 2002;93(6):2253-2256.
89. Multiple sclerosis. Available from: http://www.mayoclinic.org/multiple-sclerosis. Accessed September 5, 2011.
90. Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011;258(5):882-888.
91. Hennies C, Sternberg D, Bistulfi GL, etal. Plasma pentosidine:a potential biomarker in the management of multiple sclerosis. Mult Scler. 2011;17(2):157-163.
92. Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007;7(4):535-542.
93. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14593-14598.
94. The Merck Manual Home Health Handbook. Multiple sclerosis. Available from: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/multiple_sclerosis_ms_and_related_disorders/multiple_sclerosis_ms.html?qt=&sc=&alt=. Accessed April 26, 2012.
95. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005;139(1):152-158.
96. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med. 1971;285(27):1493-1496.
97. Moreno B, Fernandez-Diez B, Di Penta A, Villoslada P. Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Mult Scler. 2010;16(9):1102-1108.
98. Muramatsu T. Midkine: a promising molecule for drug development to treat diseases of the central nervous system. Curr Pharm Des. 2011;17(5):410-423.
99. Dasgupta S, Zhou Y, Jana M, Banik NL, Paha K. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol. 2003;170(7):3874-3882.
100. Faraco G, Cavone L, Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med. 2011;17(5-6):442-447.
101. Zhao X, Kan Q, Zhu L, Zhang GX. Matrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitis. Am J Chin Med. 2011;39(5):933-941.
102. Lutterotti A, Berger T. Advances in multiple sclerosis therapy: new oral disease-modifying agents, CML. Mult Scler. 2010;2:1-10.
103. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156(1-2):3-9.
104. Warnke C, Meyer HG, Hartung HP, Stuve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333-340.
105. Espejo C, Montalba X. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clin Immunol. 2011;142(1):84-92.
106. Osborne R. Buzz around Campath proof-of-concept trial in MS. Nat Biotechnol. 2009;27(1):6-8.
107. Taupin P. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. Expert Opin Ther Pat. 2011;21(1):111-114.
108. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9): 899-910.
109. Marmont AM. New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation. Annu Rev Med. 2000;51:115-134.
110. Kanwar JR, Sun X, Punj V, etal. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine. 2012;8(4):399-414.
111. McKinney PA. Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry. 2004;75:ii12-ii17.
112. Baumann CK, Zumwalt CB. Intracranial neoplasms. An overview. AORN J. 1989;50(2):240-242.
113. Graham CA, Cloughesy TF. Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 2004;20(4): 260-272.
114. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1992-1997. Chicago, IL: Central Brain Tumor Registry of the United States; 2000.
115. Nelson DF, Martz KL, Bonner H, etal. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17.
116. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(4):4643-4648.
117. Mazzola CA, Pollack IF. Medulloblastoma. Curr Treat Options Neurol. 2003;5(3):189-198.
118. Galanis E, Buckner J, Schomberg P. Effective chemotherapy for advanced CNS embryonal tumors in adults. J Clin Oncol. 1997;15(8):2939-2944.
119. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579-592.
120. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol. 2003;13(1):52-61.
121. Tremonts-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control. 2003;10(2): 125-137.
122. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today. 2008;13(23-24):1099-1106.
123. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90-105.
124. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55(3):425-461.
125. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. Neuro Rx. 2005;2(1):44-53.
126. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol. 2006;6(5):494-500.
127. Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114:343-347.
128. De JongWH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133-149.
129. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28(1):1-13.
130. Rapoport SI, Ohno K, Fredericks WR, Pettigrew KD. Regional cerebrovascular permeability to [14C] sucrose after osmotic opening of the blood-brain barrier. Brain Res. 1978;150(3):653-657.
131. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today. 2010;5(2):143-159.
132. Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986;7(3):314-330.
133. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid trans-cytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995;12(6):807-816.
134. Friden PM. Alkermes Inc, assignee. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates. United States Patent US5833988. November 10, 1998.
135. Pardridge WM, Wu D, Sakane T. Combined use of carboxyldirected protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res. 1998;15(4):576-582.
136. Starr CM, Zankel T, Gabathuler R. Biomarin Pharmaceutical Inc, assignee. Delivery of therapeutic compounds to the brain and other tissues. CA2525236. January 13, 2005.
137. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radio pharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest. 1997;100(7):1804-1812.
138. Forni F, Vandelli MA, Constantino L. Universita' Degli Studi Di Modena Reggio Emilia E, assignee. Drug delivery peptides for crossing blood-brain barrier. European Patent application EP20050817909. August 22, 2007.
139. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54(4):459-476.
140. Hu K, Li J, Shen Y, etal. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134(1):55-61.
141. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65-81.
142. Steiniger SC, Kreuter J, Khalansky AS, etal. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109(5):759-767.
143. Wang CX, Huang LS, Hou LB, etal. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6glioma cells of a brain tumor model. Brain Res. 2009;1261:91-99.
144. Petri B, Bootz A, Khalansky A, etal. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release. 2007;117(1):51-58.
145. Gelperina S, Maksimenko O, Khalansky A, etal. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm. 2010;74(2):157-163.
146. Kulkarni SA, Feng SS. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine. 2011;6(2):377-394.
147. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK. Poly(dl-lactide-co-glycolide) nanoparticles based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52(6):981-986.
148. Gan CW, Feng SS. Transferrin-conjugated nanoparticlesof poly(lactide)-d-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials. 2010;31(30):7748-7757.
149. Carroll RT, Bhatia D, Geldenhuys W, etal. Brain-targeted deliveryof Tempol-loaded nanoparticlesfor neurological disorders. J Drug Target. 2010;18(9):665-674.
150. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C. Lactoferrin-modified nanoparticles could mediate efficient gene deliveryto the brainin vivo. Brain Res Bull. 2010;81(6):600-604.
151. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 2008;25(11):2674-2684.
152. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010;31(5): 908-915.
153. Neely A, Perry C, Varisli B, etal. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nano. 2009;3(9):2834-2840.
154. Huang S, Li J, Han L, etal. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticlesfor glcoma. Biomaterials. 2011;32(38):6832-6838.
155. Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticlesto glioma via intravenous administration. Biomaterials. 2011;32(9):2399-2406.
156. Huile G, Shuaiqi P, Zhi Y, etal. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials. 2011;32(33):8669-8675.
157. Tian XH, Lin XN, Wei F, etal. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445-452.
158. Guo J, Gao X, Su L, etal. Aptamer-functionalized PEG-PLGA nanoparticlesfor enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010-8020.
159. Fillmore HL, Shultz MD, Henderson SC, etal. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond). 2011;6(3):449-458.
160. Li J, Feng L, Fan L, etal. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32(21):4943-4950.
161. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm. 2011;8(1): 143-152.
162. Van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A. 2009;106(1):18-23.
163. Yurko Y, Maximov V, Andreozzi E, Thompson GL, Vertegel AA. Design of biomedical nanodevices for dissolution of blood clots. Mater Sci Eng C Mater Biol Appl. 2009;29(3):737-741.
164. Marsh JN, Hu G, Scott MJ, etal. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond). 2011;6(4):605-615.
165. Baratchi S, Kanwar RK, Kanwar JR. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS One. 2011;6(1):e15865.
166. Baratchi S, Kanwar RK, Antonio Cheung CH, Kanwar JR. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol. 2010;227(1-2):120-132.
167. Wynne A, Kanwar RK, Khanna R, Kanwar JR. Recent advances on the possible neuroprotective activities of Epstein-Barr virus oncogene BARF1 protein in chronic inflammatory disorders of central nervous system. Curr Neuropharmacol. 2010;8(3):268-275.
168. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain. 2004;127(Pt 6):1313-1331.
169. Kanwar JR, Kanwar RK, Wang D, Krissansen GW. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol. 2000;78(6):641-645.
170. Kanwar JR, Harrison JEB, Wang D, etal. b7integrins contribute to demyelinating disease of the central nervous system. J Neuroimmunol. 2000;103(2):146-152.
171. Wengel J. Synthesis of 3'-C-and 4'-C-branched oligonucleotides and the development of locked nucleic acid (LNA). Acc Chem Res. 1999;32:301-310.